https://www.selleckchem.com/pr....oducts/pilaralisib-x
The AMPK pathway was central to metformin protective action. Within COPDGene, participants taking metformin compared to those not on it had slower progression of emphysema (-0.92%, CI; -1.7 to -0.14%, p = 0.02) and adjusted lung density decrease (2.2 g/L; 95% CI 0.43 to 4.0 g/L, p = 0.01). Metformin protected against CS-induced lung, renal, and muscle injury, mitochondrial dysfunction, and UPR-ER stress in mice. In humans, metformin use was associated with lesser emphysema progression over time. Our results provide a rationale
Like
Comment
Share
